Raymond James Financial Inc. Sells 195,286 Shares of Hims & Hers Health, Inc. $HIMS

Key Points

• Raymond James Financial Inc. reduced its stake in Hims & Hers Health, Inc. by 26.2%, owning approximately 0.25% of the company, valued at $16.29 million.
• Hims & Hers Health reported a net loss in its recent quarterly earnings, with $0.17 earnings per share, missing the consensus estimate by $0.01.
• Insiders sold significant shares recently, with CEO Andrew Dudum selling 128,127 shares valued at over $5.77 million, leading to a 58.87% decrease in his position.

Raymond James Financial Inc. cut its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 26.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 551,120 shares of the company's stock after selling 195,286 shares during the quarter. Raymond James Financial Inc. owned 0.25% of Hims & Hers Health worth $16,286,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Yong Rong HK Asset Management Ltd raised its position in Hims & Hers Health by 41.2% in the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after purchasing an additional 700,100 shares during the last quarter. Northern Trust Corp raised its position in Hims & Hers Health by 17.9% in the fourth quarter. Northern Trust Corp now owns 2,038,202 shares of the company's stock valued at $49,284,000 after purchasing an additional 308,886 shares during the last quarter. Nuveen LLC bought a new position in Hims & Hers Health in the first quarter valued at about $58,403,000. Finally, Two Sigma Investments LP raised its position in Hims & Hers Health by 37.9% in the fourth quarter. Two Sigma Investments LP now owns 1,967,354 shares of the company's stock valued at $47,571,000 after purchasing an additional 540,274 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,571 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.53, for a total value of $114,486.63. Following the completion of the sale, the insider owned 150,450 shares of the company's stock, valued at approximately $6,699,538.50. This trade represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $43.69, for a total value of $505,973.89. Following the completion of the sale, the chief financial officer directly owned 116,806 shares of the company's stock, valued at $5,103,254.14. This trade represents a 9.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Down 4.0%

NYSE HIMS traded down $1.76 during trading hours on Friday, hitting $42.36. 16,080,388 shares of the company's stock were exchanged, compared to its average volume of 29,952,310. The stock has a 50-day simple moving average of $49.98 and a 200 day simple moving average of $45.82. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The firm has a market cap of $9.57 billion, a price-to-earnings ratio of 52.95, a PEG ratio of 2.98 and a beta of 2.08. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the business earned $0.06 EPS. The company's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HIMS. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Finally, UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Reduce" and a consensus target price of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.